Alnylam Pharmaceuticals | ALNY - Interest Expense On Debt

Stock Price
286.98
Daily Change
-6.47 -2.20%
Monthly
-10.36%
Yearly
0.59%
Q2 Forecast
281.21

Alnylam Pharmaceuticals reported $69.29M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Moderna USD 11.49B 36B Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Takeda JPY 43.65B 79.98B Mar/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 4.7M 2.65M Mar/2026